Background: The aim of this study was to assess the patients’ global impression (PGI) after symptom management, as well as the achievement of personalized symptom goals (PSG). The secondary outcome was to assess related factors. Subjects, Materials, and Methods: Advanced cancer patients admitted to palliative care units rated symptom intensity by using the Edmonton Symptom Assessment Score (ESAS) at admission and then after 1 week. For each symptom, patient-reported PGI and PSG, as well as the rate of PSG response, were evaluated. Results: Eight hundred seventy-six patients were taken into consideration for this study. A mean of 1.71–2.16 points was necessary to perceive a bit better improvement of symptom intensity. Most patients had a PSG of ≤3. A statistically significant number of patients achieved their PSG after starting palliative care. Patients with high intensity of ESAS items at admission achieved a more favorable PGI response. In the multivariate analysis, symptom intensity and PSG were the most frequent factors independently associated to a best PGI, whereas high levels of Karnofsky had a lower odd ratio. Conclusion: PSG and PGI seem to be relevant for patients’ assessment and decision-making process, translating in terms of therapeutic intervention. Some factors may be implicated in determining the individual target and clinical response. Implications for Practice: Personalized symptom goals and global impression of change are relevant for patients’ assessment and decision-making process, translating in terms of therapeutic intervention. Some factors may be implicated in determining the individual target and clinical response.

Personalized Symptom Goals and Patient Global Impression on Clinical Changes in Advanced Cancer Patients / Mercadante S.; Adile C.; Lanzetta G.; Mystakidou K.; Maltoni M.; Guilherme Soares L.; De Santis S.; Ferrera P.; Valenti M.; Rosati M.; Rossi R.; Cortegiani A.; Masedu F.; Marinangeli F.; Aielli F.. - In: THE ONCOLOGIST. - ISSN 1083-7159. - ELETTRONICO. - 24:2(2019), pp. 239-246. [10.1634/theoncologist.2017-0668]

Personalized Symptom Goals and Patient Global Impression on Clinical Changes in Advanced Cancer Patients

Maltoni M.;Rossi R.;
2019

Abstract

Background: The aim of this study was to assess the patients’ global impression (PGI) after symptom management, as well as the achievement of personalized symptom goals (PSG). The secondary outcome was to assess related factors. Subjects, Materials, and Methods: Advanced cancer patients admitted to palliative care units rated symptom intensity by using the Edmonton Symptom Assessment Score (ESAS) at admission and then after 1 week. For each symptom, patient-reported PGI and PSG, as well as the rate of PSG response, were evaluated. Results: Eight hundred seventy-six patients were taken into consideration for this study. A mean of 1.71–2.16 points was necessary to perceive a bit better improvement of symptom intensity. Most patients had a PSG of ≤3. A statistically significant number of patients achieved their PSG after starting palliative care. Patients with high intensity of ESAS items at admission achieved a more favorable PGI response. In the multivariate analysis, symptom intensity and PSG were the most frequent factors independently associated to a best PGI, whereas high levels of Karnofsky had a lower odd ratio. Conclusion: PSG and PGI seem to be relevant for patients’ assessment and decision-making process, translating in terms of therapeutic intervention. Some factors may be implicated in determining the individual target and clinical response. Implications for Practice: Personalized symptom goals and global impression of change are relevant for patients’ assessment and decision-making process, translating in terms of therapeutic intervention. Some factors may be implicated in determining the individual target and clinical response.
2019
Personalized Symptom Goals and Patient Global Impression on Clinical Changes in Advanced Cancer Patients / Mercadante S.; Adile C.; Lanzetta G.; Mystakidou K.; Maltoni M.; Guilherme Soares L.; De Santis S.; Ferrera P.; Valenti M.; Rosati M.; Rossi R.; Cortegiani A.; Masedu F.; Marinangeli F.; Aielli F.. - In: THE ONCOLOGIST. - ISSN 1083-7159. - ELETTRONICO. - 24:2(2019), pp. 239-246. [10.1634/theoncologist.2017-0668]
Mercadante S.; Adile C.; Lanzetta G.; Mystakidou K.; Maltoni M.; Guilherme Soares L.; De Santis S.; Ferrera P.; Valenti M.; Rosati M.; Rossi R.; Cortegiani A.; Masedu F.; Marinangeli F.; Aielli F.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/868659
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact